⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IMRX News
Immuneering Corporation Class A Common Stock
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
globenewswire.com
IMRX
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
globenewswire.com
IMRX
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
globenewswire.com
IMRX
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
globenewswire.com
IMRX
Form 8-K
sec.gov
IMRX
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
globenewswire.com
IMRX
Immuneering to Present at the Leerink Global Healthcare Conference
globenewswire.com
IMRX
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
globenewswire.com
IMRX
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
globenewswire.com
IMRX
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
globenewswire.com
IMRX